TherapeuticsMD (TXMD) Liabilities and Shareholders Equity (2010 - 2026)

TherapeuticsMD (TXMD) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $37.6 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 1.71% year-over-year to $37.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $152.4 million (down 2.76% YoY) and the FY2025 annual result came in at $37.7 million, down 3.0% from the prior year.
• Liabilities and Shareholders Equity held at $37.6 million in Q1 2026, from $37.7 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $146.2 million in Q2 2022 to a low of $37.6 million in Q1 2026.
• A 5-year average of $62.5 million and a median of $42.1 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity slumped 63.28% — and 2026, when it fell 1.71%.
• Tracing TXMD's Liabilities and Shareholders Equity over 5 years: stood at $90.5 million in 2022, then tumbled by 52.12% to $43.3 million in 2023, then retreated by 10.36% to $38.8 million in 2024, then dropped by 3.0% to $37.7 million in 2025, then declined by 0.2% to $37.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $37.6 million (Q1 2026), $37.7 million (Q4 2025), and $38.7 million (Q3 2025), per Business Quant data.